Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 04, 2026 | June 05, 2026 |
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Director | June 08, 2026 | June 11, 2026 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 08, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-04 | Direct | 8,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 8,000 · Balance 8,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.
Axsome Therapeutics, Inc.
Report date June 08, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 829 |
Ending reported balance
After 2026-06-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-08 · Exercise / conversion · Acquired 1,429 · Balance 1,429 F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Row 2 · 2026-06-09 · Sale · Disposed 300 · Balance 1,129 F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. Row 3 · 2026-06-10 · Sale · Disposed 300 · Balance 829 F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-08 · Exercise / conversion · Disposed 1,429 · Balance 0 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ELI LILLY & Co
Report date April 13, 2018 · Filed February 01, 2019 · Amendment
Section 16 reporting ended · disclosed 2019-02-01. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,685 |
Reported balance
After 2018-04-16 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-04-16 · Sale · Disposed 17,379 · Balance 40,685 F1: This amendment is being filed to correct the total holdings held by the reporting person following the transaction reported on the original Form 4 filed on April 17, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the total holdings held by the reporting person following the transaction reported on the original Form 4 filed on April 17, 2018.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 9,345 · Balance 0 F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 9,306 · Balance 0 F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F3: Each RSU (as defined in footnote 5 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F5: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F4: The Ordinary Shares subject to the RSUs vest on July 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly.
F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F3: Each RSU (as defined in footnote 5 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F4: The Ordinary Shares subject to the RSUs vest on July 27, 2024.
F5: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 300 | $246.18 | $73,854.00 |
DisclosureSEC source: 0001193125-26-266435 · ownership.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 829 F3 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4 · shares: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 300 | $237.21 | $71,163.00 |
DisclosureSEC source: 0001193125-26-266435 · ownership.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,129 F3 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4 · shares: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. Read SEC document |
| June 08, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionRestricted Stock Units · Derivative | 1,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266435 · ownership.xml · derivative · entry 4 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| June 08, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 1,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-266435 · ownership.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:18 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 1,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-264040 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,721 Underlying: Common Stock · 1,721 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:50 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0001193125-26-259822 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:42 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010843 · ownership.xml · derivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:42 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010843 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 1,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084554 · ownership.xml · derivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429 Underlying: Common Stock · 1,429 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant, June 6, 2026. F3 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant, June 6, 2026. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 3,166 | $0.00 Strike: $111.91 | $0.00 |
DisclosureSEC source: 0000950170-25-084554 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,166 Underlying: Common Stock · 3,166 shares Expires 2035-06-06 F1 · derivative.exercise_date: The options vest in full on the one-year anniversary of the date of grant, June 6, 2026. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $15.81 | $0.00 |
DisclosureSEC source: 0000950170-25-083703 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 01:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 1,312 | $0.00 Strike: $137.75 | $0.00 |
DisclosureSEC source: 0000950170-25-027090 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,312 Underlying: Common Stock · 1,312 shares Expires 2035-02-20 F1 · shares: Represents 1,312 options elected to be received in lieu of cash compensation earned in 2024. All of such options are immediately exercisable. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 22:51 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0000950170-24-135921 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 10, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:32 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 5,799 | $0.00 Strike: $73.90 | $0.00 |
DisclosureSEC source: 0000950170-24-071965 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,799 Underlying: Common Stock · 5,799 shares Expires 2034-06-07 F1 · derivative.exercise_date: The options vest in full on the one-year anniversary of the date of grant, June 7, 2025. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $15.06 | $0.00 |
DisclosureSEC source: 0000950170-24-066604 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2034-05-29 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 29, 2025 and (2) the date of the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:18 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 191 | $0.00 Strike: $84.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023351 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191 Underlying: Common Stock · 191 shares Expires 2034-02-26 F1 · derivative.exercise_date: Represents 191 options elected to be received in lieu of cash compensation earned in 2023. All of such options are immediately exercisable. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:22 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0000950170-23-069112 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 7, 2023. Read SEC document |
| October 10, 2023 Filed Oct 13, 2023 00:33 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 5,873 | $0.00 Strike: $70.56 | $0.00 |
DisclosureSEC source: 0001209191-23-052736 · doc4.xml · derivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,873 Underlying: Common Stock · 5,873 shares Expires 2033-10-10 F2 · derivative.exercise_date: The option will vest in equal annual installments over three years such that the option will be fully vested on October 10, 2026. Read SEC document |
| October 10, 2023 Filed Oct 13, 2023 00:33 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 1,502 | $0.00 Strike: $70.56 | $0.00 |
DisclosureSEC source: 0001209191-23-052736 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,502 Underlying: Common Stock · 1,502 shares Expires 2033-10-10 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, October 10, 2024. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerRestricted Stock Units · Derivative | 4,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052375 · doc4.xml · derivative · entry 3 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,016 shares Expires 2024-07-27 F3 · derivative.exercise_price: Each RSU (as defined in footnote 5 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F5 · price: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F4 · derivative.exercise_date: The Ordinary Shares subject to the RSUs vest on July 27, 2024. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerOrdinary Shares | 9,306 | $116.50 | $1,084,149.00 |
DisclosureSEC source: 0001209191-23-052375 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · shares: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2 · price: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerOrdinary Shares | 9,345 | $116.50 | $1,088,692.50 |
DisclosureSEC source: 0001209191-23-052375 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2 · price: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 16:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 4,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043697 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,016 Underlying: Ordinary shares · 4,016 shares Expires 2024-07-27 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001209191-23-032891 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2024 and (2) the date of the Issuer's 2024 annual meeting of stockholders. Read SEC document |
| April 28, 2023 Filed May 2, 2023 19:26 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 3,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026755 · doc4.xml · derivative · entry 4 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,913 shares Expires 2023-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 28, 2023 Filed May 2, 2023 19:26 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 1,879 | $111.16 | $208,869.64 |
DisclosureSEC source: 0001209191-23-026755 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,034 Read SEC document |
| April 28, 2023 Filed May 2, 2023 19:26 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 3,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026755 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| December 21, 2022 Filed Dec 24, 2022 00:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0000899243-22-039326 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022. Read SEC document |
| May 25, 2022 Filed May 27, 2022 21:00 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-22-032606 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2023 and (2) the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 4,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026473 · doc4.xml · derivative · entry 4 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 4,223 shares Expires 2022-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 1,658 | $98.56 | $163,412.48 |
DisclosureSEC source: 0001209191-22-026473 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 16,617 Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 4,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-026473 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 28, 2022 Filed May 2, 2022 18:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 3,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026473 · doc4.xml · derivative · entry 3 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,913 Underlying: Ordinary shares · 3,913 shares Expires 2023-04-28 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:03 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-21-035404 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| May 06, 2021 Filed May 8, 2021 00:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $29.49 | $0.00 |
DisclosureSEC source: 0000899243-21-018766 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2031-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 19:02 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 11,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029367 · doc4.xml · derivative · entry 4 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 11,098 shares Expires 2021-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 19:02 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 4,357 | $94.62 | $412,259.34 |
DisclosureSEC source: 0001209191-21-029367 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 14,052 Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 19:02 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 11,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029367 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 19:02 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 4,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029367 · doc4.xml · derivative · entry 3 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,223 Underlying: Ordinary shares · 4,223 shares Expires 2022-04-29 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:44 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.47 | $0.00 |
DisclosureSEC source: 0001209191-20-036640 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders. Read SEC document |
| May 08, 2020 Filed May 12, 2020 10:32 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.49 | $0.00 |
DisclosureSEC source: 0000899243-20-012777 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2030-05-07 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 8, 2020. Read SEC document |
| May 02, 2020 Filed May 4, 2020 17:31 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 12,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026890 · doc4.xml · derivative · entry 4 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 12,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On August 1, 2019, the reporting person was granted 12,036 restricted stock units, vesting in full on May 2, 2020. F2 · derivative.expiration_date: On August 1, 2019, the reporting person was granted 12,036 restricted stock units, vesting in full on May 2, 2020. Read SEC document |
| May 02, 2020 Filed May 4, 2020 17:31 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 4,725 | $35.62 | $168,304.50 |
DisclosureSEC source: 0001209191-20-026890 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 7,311 Read SEC document |
| May 02, 2020 Filed May 4, 2020 17:31 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 12,036 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-026890 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 12,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 30, 2020 Filed May 4, 2020 17:31 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 11,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026890 · doc4.xml · derivative · entry 3 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,098 Underlying: Ordinary shares · 11,098 shares Expires 2021-04-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 16:54 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 12,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044600 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,036 Underlying: Ordinary shares · 12,036 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 17, 2019 Filed May 17, 2019 23:36 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001144204-19-027161 · tv521927_4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 17, 2020 and (ii) the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:45 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $42.09 | $0.00 |
DisclosureSEC source: 0001144204-18-032466 · tv495556_4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-30 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 30, 2019 and (ii) the date of the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| April 16, 2018 Filed Apr 17, 2018 19:29 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 17,379 | $80.08 | $1,391,710.32 |
DisclosureSEC source: 0000059478-18-000123 · wf-form4_152399337145959.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,273 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $80.00 to $80.27. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2018 Filed Feb 1, 2019 19:38 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 17,379 | $80.08 | $1,391,710.32 |
DisclosureSEC source: 0000059478-19-000022 · wf-form4a_154904987716452.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,685 F1 · balance_after: This amendment is being filed to correct the total holdings held by the reporting person following the transaction reported on the original Form 4 filed on April 17, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.